To assure continued industry growth, Chinese authorities recognize the importance of enhancing their country's IP protection
systems for both domestic and foreign biologics. The fact that Chinese companies are using the court systems and lawsuits
to seek remedies indicates a major change in the Chinese pharmaceuticals business environment. China's large domestic market
potential and its solid competence in producing biogenerics are key factors driving its future direction.
REFERENCES:
1. The journey of generic drugs to overturn innovative drugs (in Chinese). Medicine Economic News. 2004; Dec. 30.
2. http://
http://www.oecd.org/document/25/0,2340,en_2649_201185_34967193_1_1_1_1,00.html.
3. http://
http://www.sfda.gov.cn/cmsweb/webportal/W4291/A64003794.html.
4. China's bio-tech and industry appears rapid expansion trend. A report (in Chinese). 2006; Apr. 22. Available at http://
http://www.chinabgao.com/freereports/10264.html.
5. Rader R. Biopharmaceutical products in US and European markets. 5th Ed. BioPlan Associates, Inc. 2006.
Eric Langer is president of BioPlan Associates, Rockville, MD, 301.921.9074. elanger@bioplanassocicates.com
|
